| Full text | |
| Author(s): |
Faiao-Flores, Fernanda
[1]
;
Quincoces Suarez, Jose Agustin
[2]
;
Fruet, Andrea Costa
[1]
;
Maria-Engler, Silvya Stuchi
[1]
;
Pardi, Paulo Celso
[3]
;
Maria, Durvanei Augusto
[4]
Total Authors: 6
|
| Affiliation: | [1] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Chem & Toxicol, Sao Paulo - Brazil
[2] Anhanguera Univ Sao Paulo, Organ Synth Lab, UNIAN, Sao Paulo - Brazil
[3] Anhanguera Univ Sao Paulo, Lab Expt Pathol, UNIAN, Sao Paulo - Brazil
[4] Butantan Inst, Biochem & Biophys Lab, Sao Paulo - Brazil
Total Affiliations: 4
|
| Document type: | Journal article |
| Source: | PLoS One; v. 10, n. 3 MAR 5 2015. |
| Web of Science Citations: | 13 |
| Abstract | |
Malignant melanoma is a highly aggressive form of skin cancer with a high mortality rate if not discovered in early stages. Although a limited number of treatment options for melanoma currently exist, patients with a more aggressive form of this cancer frequently decline treatment. DM-1 is a sodium phenolate and curcumin analog with proven anticancer, anti-proliferative and anti-metastatic properties. In this paper, the DM-1 compound showed in vivo antitumor activity alone or in combination with chemotherapeutic DTIC in B16F10 melanoma-bearing mice. Beneficial effects such as melanoma tumor burden reduction with pyknotic nuclei, decreased nuclei/cytoplasmic ratio and nuclear degradation occurred after DM-1 treatment. No toxicological changes were observed in the liver, kidneys, spleen and lungs after DM-1 monotherapy or DTIC combined therapy. DTIC+DM-1 treatment induced the recovery of anemia arising from melanoma and immunomodulation. Both DM-1 treatment alone and in combination with DTIC induced apoptosis with the cleavage of caspase-3, -8 and -9. Furthermore, melanoma tumors treated with DM-1 showed a preferential apoptotic intrinsic pathway by decreasing Bcl-2/Bax ratio. Considering the chemoresistance exhibited by melanoma towards conventional chemotherapy drugs, DM-1 compound in monotherapy or in combination therapy provides a promising improvement in melanoma treatment with a reduction of side effects. (AU) | |
| FAPESP's process: | 08/56397-8 - Avaliação da atividade antitumoral do composto sintético DM-1 e terapia de captação de nêutrons por boro (BNCT) associados ao quimioterápico dacarbazina no tratamento do melanoma |
| Grantee: | FERNANDA FAIÃO FLORES |
| Support Opportunities: | Scholarships in Brazil - Doctorate (Direct) |
| FAPESP's process: | 11/50435-8 - Synthesis of biologically active phenols and derivatives |
| Grantee: | José Agustín Pablo Quincoces Suárez |
| Support Opportunities: | Regular Research Grants |